Aptorum established a Scientific Advisory Board to provide valuable input from a scientific perspective towards target acquisition or in-licensing opportunities of life science innovations, together with the guardianship from the Senior Clinical Advisors, to perform an 8-Dimensions assessment process, ensuring the market potential and scientific quality of our pipeline and high visibility to success.
Senior Clinical Advisor
Dr. Agrawal, MD, has been serving as the Director of Head and Neck Surgical Oncology, and Professor of Surgery at The University of Chicago School of Medicine since October 2015. He is specialized in management of patients with benign and malignant tumors of the head and neck, and has been practicing Otolaryngology - Head and Neck Surgery, at The University of Chicago Medicine, and Center for Advanced Medicine, both in Chicago since 2009. Dr. Agrawal's work has achieved international recognition in the field of head and neck surgical oncology, as well as head and neck cancer genetics. Under his leadership, a team of researchers completed a landmark study that examined the genome of head and neck squamous cell carcinoma. His team has published extensively in the genomic landscapes of major head and neck cancers, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, medullary thyroid cancer, adenoid cystic carcinoma, and mucoepidermoid carcinoma. Dr. Agrawal then applied these findings to identify tumor DNA as a biomarker that improves cancer diagnostics in the saliva and plasma of patients with head and neck squamous cell carcinoma. His researches focus on the application of cancer genetics to design diagnostic approaches to reduce morbidity and mortality from head and neck cancer. In addition to his clinical and research contributions, Dr. Agrawal is an accomplished educator-teaching medical students, residents, and fellows about the management of patients with head and neck cancer. Prior to joining the University of Chicago, Dr. Agrawal was an associate professor at Johns Hopkins University, where he completed his medical training in 2001, followed by internship and residency. In addition, Dr. Agrawal was granted fellowships from the Memorial Sloan Kettering Cancer Center, New York (Head and Neck Surgical Oncology), and from Johns Hopkins University School of Medicine, Baltimore (Molecular Genetics). He holds numerous Memberships from accredited American medical associations and institutions.
Senior Scientific Advisor
Dr. Lawrence Baum is an Adjunct Associate Professor in the School of Pharmacy at The Chinese University of Hong Kong since 2014, and Research Officer in the Faculty of Medicine at The University of Hong Kong since September 2017. He served as a Honorary Associate Professor in The University of Hong Kong during 2014 to 2018. Prior to that, he served as an Associate Professor during 2008 to 2014, and assistant professor during 2002 to 2008 in The Chinese University of Hong Kong. Dr. Lawrence Baum is a member of the Hong Kong Society of Neurosciences and Hong Kong Society of Medical Genetics. Dr. Lawrence Baum is specialist in brain diseases, focusing on depression, epilepsy genetics, and Alzheimer's disease treatment. He received his Ph.D. in Neurosciences at UC San Diego in 1994.
Senior Scientific Advisor
Dr. Francis Szele is an Associate Professor and University Lecturer in the Department of Physiology, Anatomy & Genetics at the University of Oxford since 2007. He has several decades research experience in adult neurogenesis and has investigated stem cells, neurogenesis, and migration in the postnatal subventricular zone (SVZ). Dr. Francis Szele was an Assistant Professor at the Northwestern University during 1999 to 2007. Prior to that, he He did a postdoctoral fellowship in Connie Cepko’s laboratory at Harvard Medical School, Boston, USA, during 1994 to 1999. Dr. Francis Szele received his Ph.D. in Biology at the The University of Pennsylvania, U.S in 1994 where he carried out one of the first studies showing increased neurogenesis after brain injury.
In addition to serving on the Scientific Advisory Board, Dr. Majzner provides specific scientific advice and support for certain targeted clinical development aspects of our repurposed drug candidate SACT-1. Dr. Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at the Stanford University Medical Center. Prior to joining Stanford, he worked in the laboratory of Dr. Crystal Mackall at the National Cancer Institute. His research interests lie in the optimization of chimeric antigen receptor (CAR) T cell therapies for sarcomas and other solid tumors. Dr. Majzner received his M.D. from Harvard Medical School, and completed his pediatric residency at Columbia University and fellowship in pediatric hematology-oncology at the joint program of Johns Hopkins University and the National Cancer Institute.
MR. WILLIAM WEISS currently is Director of Preclinical Service and Instructor of Pharmaceutical Sciences, College of Pharmacy, University of North Texas. He has 38 years of experience in drug discovery and development of antimicrobials including antibiotics, antivirals and antifungals. He was a Director of Cumbre Pharmaceutics Inc.; Group leader at Wyeth for 17years; and employed at Schering-Plough for 7 years. He graduated from Rutgers University with a B.Sc degree in Microbiology, and received his M.Sc from Penn State University and Fairleigh Dickinson University.
Dr. Chan is currently a Senior Advisor of Cornerstone Intellectual Property Foundation in Taiwan. He is also serving as an adjunct professor at the Graduate Institute of Intellectual Property, College of Commerce, National Chengchi University and adjunct professor and advisor at the Research Center for Drug Discovery, National Yang Ming University in Taipei, Taiwan. Dr. Chan co-founded GloboMax LLC, a drug development organization, in Hanover, Maryland, in July 1997, and served as a consultant for numerous multi-national pharmaceutical and biotech firms in the U.S, Europe and Asia. GloboMax LLC was acquired by ICON, plc. in August 2003, and Dr. Chan exited the operation. Prior to that, he joined the FDA in 1995 as a Director of Division of Bioequivalence, Office of Generic Drugs, responsible for managing and approval of generic drugs in the States. Dr. Chan had worked for Ciba-Geigy Corporation in Ardsley, New York, for 15 years, and held various senior and management positions. Dr. Chan also has extensive experience in new and generic drug development in executing preclinical animal studies, bioassay development, Phases I to VI Pharmacokinetics, pharmacodynamics, bioavailability, bioequivalence studies, outside contract, regulatory submission, advanced drug delivery systems, and all phases of new drug development. In addition, he has served as Professor/adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore during 1996 - 2009 and also as Adjunct Professor and National Board of Advisor, College of Pharmacy, University of Minnesota during 1984 - 2006. He has published more than 150 abstracts and research articles in peer-reviewed journals and delivered over 200 professional presentations. He was elected as Fellow of the American Association of Pharmaceutical Scientists (“AAPS”) in 1995 for his scientific accomplishments on drug absorption in humans. Although much of his career was based in the United States, Dr. Chan has been assisting Asian pharmaceutical and biotech companies for over 14 years. He has organized numerous workshops and conferences in the PRC, Taiwan, Hong Kong, Singapore and Korea. He lectures frequently in Asia and serves as a scientific advisor for many regulatory agencies in Asia. Over the last several years, he has successfully assisted many Asian companies in their technology transfers and licensing deals to and from the U.S., as well as with numerous regulatory submissions to the FDA. Dr. Chan obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota in January 1980.